AAA
ALLO icon

Affinity Asset Advisors’s Allogene Therapeutics ALLO Stock Holding History

Affinity Asset Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400,000
Closed -$1.28M – 98
2023
Q4 		$1.28M Buy
+400,000
New +$1.13M 0.23% 66

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Affinity Asset Advisors's ALLO Position: Q1 2024 in Review

Affinity Asset Advisors sold out of Allogene Therapeutics (ALLO) in Q1 2024, closing a stake of 400,000 shares — an estimated $1.28M sold.

Affinity Asset Advisors first reported a position in ALLO in Q4 2023 and held it in 1 quarter. The position peaked at $1.28M in Q4 2023. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

  • Affinity Asset Advisors reported no remaining Allogene Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 400,000 Allogene Therapeutics shares in Q1 2024, an estimated $1.28M.
  • Affinity Asset Advisors first reported a position in Allogene Therapeutics in Q4 2023 and held it in 1 quarter.
  • Affinity Asset Advisors's Allogene Therapeutics position peaked at $1.28M in Q4 2023.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.